Showing 2331-2340 of 6036 results for "".
- RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disordershttps://modernod.com/news/retipharma-secures-funding-to-develop-treatments-of-degenerative-eye-disorders/2479680/RetiPharma has announced that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be used to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds usi
- Carl Zeiss Meditec to Acquire IanTECH, Maker of the miLOOP Device for Cataract Surgeryhttps://modernod.com/news/carl-zeiss-meditec-to-acquire-iantech-maker-of-the-miloop-device-for-cataract-surgery/2479758/Carl Zeiss Meditec announced it has entered into an agreement to acquire IanTECH, the manufacturer of the miLOOP device for cataract surgery. miLOOP is a microinterventional device designed to deliver energy-free endocapsular lens fragmentation independent of phaco energy. Terms of the d
- Altris.AI Partners With Huvitz for Development of AI-Based Retinal Detectionhttps://modernod.com/news/altris-ai-the-new-era-of-retinal-diagnosis-is-coming/2479785/Artificial intelligence company Altris.Al announced it has signed an agreement with South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co. aimed at the development of customized deep learning solutions for retinal diseases detection. Terms of the deal were not disclo
- Department of Defense Grant for Clinical Trial of Stem Cell Therapy for Eye Injurieshttps://modernod.com/news/department-of-defense-grant-for-clinical-trial-of-stem-cell-therapy-for-eye-injuries/2479809/Researchers at the University of Illinois at Chicago have received a 4-year, $5.25 million grant from the U.S. Department of Defense to lead a multisite clinical trial to test the efficacy of a stem cell-based treatment for eye injuries. The treatment uses mesenchymal stem cells—cells that
- CooperVision Introduces Online Training to Help ECPs Upgrade Contact Lens Patients to Silicone Hydrogel 1-Day Lenseshttps://modernod.com/news/coopervision-introduces-online-training-to-help-ecps-upgrade-contact-lens-patients-to-silicone-hydrogel-1-day-lenses/2479834/To help eye care professionals grow their silicone hydrogel 1-day contact lens business, CooperVision is unveiling a new, comprehensive online training program that can be completed at any place and time. The web-based training and on-demand webinar focus on teaching practitioners and staff how t
- Ziemer to Implement Low Energy Lenticule Extraction Applications for its Femtosecond Laser Platformhttps://modernod.com/news/ziemer-announces-to-implement-low-energy-lenticule-extraction-applications-to-its-femtosecond-laser-platform/2479888/Ziemer Ophthalmic Systems announced plans to incorporate lenticule extraction capabilities for its flagship LDV Z8 femtosecond laser system.1 “From the very first days of developing the femtosecond l
- Contact Lens Companies Seek Summary Judgment in Lawsuit Over Minimum Pricinghttps://modernod.com/news/contact-lens-companies-seek-summary-judgment-in-lawsuit-over-minimum-pricing/2479910/Three contact lens companies and a distributor, who are defendants in a class-action lawsuit over pricing, filed a motion seeking a summary judgment in the matter in U.S. District Court for the Middle District of Florida here earlier this week, according to a
- ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-on-qr-110-for-lebers-congenital-amaurosis-10/2479967/ProQR Therapeutics announced the publication of a peer-reviewed manuscript describing the preclinical validation for the use of QR-110 in the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal
- Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza/2480009/Ocular Therapeutix announced that it has received acknowledgement from the FDA that the new drug application (NDA) for Dextenza has been received. Dextenza (dexamethasone insert) 0.4 mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery. T
- LensGen Announces Funding And Patent Successhttps://modernod.com/news/lensgen-announces-funding-and-patent-success/2480017/LensGen, a private California company developing the world’s first modular, fluid-optic, curvature changing IOL, is reporting significant progress in its effort to transform how presbyopia is addressed, according to a company news release. The company successfully achieved a key clin